CNS Pharmaceuticals
Manufacturing · Texas, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2100 West Loop S Ste 900, Houston, Texas...Phone Number
(800) 946-9185Website
www.cnspharma.comRevenue
<$5 MillionStock Symbol
CNSPIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About CNS Pharmaceuticals
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.Explore more
CNS Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CNS Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when CNS Pharmaceuticals launches new products
Earning: See what the market has to say on CNS Pharmaceuticals recently announced quarterly report
Funding: Get notified immidiatlly once CNS Pharmaceuticals has new funding data
Click to see if CNS Pharmaceuticals had a recent Job posting/layoffs
Check out if CNS Pharmaceuticals is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
CNS Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at CNS Pharmaceuticals
Website visits: Recent activity has been detected on your website
Check if CNS Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined CNS Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to CNS Pharmaceuticals
Compare insights from companies similar to CNS Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CNS Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
CNS Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about CNS Pharmaceuticals.
CNS Pharmaceuticals financials insights
Gather financial insights about CNS Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Private Equity
$22.5M
CNS Pharmaceuticals Tech Stack
A closer look at the technologies used by CNS Pharmaceuticals
Most Recent Scoops
Funding
Funding
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
Eric Faulkner has recently joined the organization as Chief Technology Officer.
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
CNS Pharmaceuticals News & Media
CNS Pharmaceuticals (NASDAQ: CNSP) Secures $22.5M Private Placement Financing
Investor Brand Network Press Release.CNS Pharmaceuticals raises $22.5M in private placement | CNSP 8-K Filing - Stock Titan
CNS Pharmaceuticals is raising about $22.5M via stock and pre-funded warrants, adding resale registration obligations, equity-sale restrictions, and appointing a new independent director.CNS Pharmaceuticals pivots to neurology, oncology assets | CNSP Stock News
Company will seek preclinical and clinical neurology and oncology assets and market berubicin and TPI 287 for out-licensing as it shifts strategy.CNS Pharmaceuticals Files Initial Beneficial Ownership Statement for CTO Eric Faulkner
CNS Pharmaceuticals Inc. filed an initial statement of beneficial ownership naming Eric Faulkner, Chief Technology Officer, as the reporting person. The full filing can be accessed through the link below. Disclaimer: This news brief was created by...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CNS Pharmaceuticals
Sign Up For FreeTo access detailed company insights
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. CNS Pharmaceuticals, I... Read More
